Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Shanghai Haohai Biological Technology Co Ltd
PP&E Net
Shanghai Haohai Biological Technology Co Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
|
PP&E Net
¥1.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
PP&E Net
¥9.3B
|
CAGR 3-Years
54%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
PP&E Net
¥5.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
PP&E Net
¥3.6B
|
CAGR 3-Years
30%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
PP&E Net
¥2.9B
|
CAGR 3-Years
46%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
PP&E Net
¥700.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai Haohai Biological Technology Co Ltd
Glance View
Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.
See Also
What is Shanghai Haohai Biological Technology Co Ltd's PP&E Net?
PP&E Net
1.5B
CNY
Based on the financial report for Dec 31, 2023, Shanghai Haohai Biological Technology Co Ltd's PP&E Net amounts to 1.5B CNY.
What is Shanghai Haohai Biological Technology Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
16%
Over the last year, the PP&E Net growth was 10%. The average annual PP&E Net growth rates for Shanghai Haohai Biological Technology Co Ltd have been 14% over the past three years , 16% over the past five years .
You don't have any saved screeners yet